Nexium (Esomeprazole Magnesium Trihydrate)

Esomeprazole, the active ingredient in Nexium, is a proton pump inhibitor presented as an oral tablet for oral use. It suppresses gastric acid production and is used to manage acid‑related disorders such as gastro‑oesophageal reflux disease and ulcer conditions in adults. GNH USA supplies Nexium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexium, a proton pump inhibitor, is indicated for several acid‑related gastrointestinal conditions. - Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of the esophageal lining. - Erosive oesophagitis: facilitates mucosal repair and decreases further acid injury. - Prevention of NSAID‑induced gastric ulcers: protects the stomach lining in patients taking non‑steroidal anti‑inflammatory drugs. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens by reducing gastric acidity.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhoea: loose stools that may resolve with continued therapy. - Nausea: feeling of queasiness, sometimes accompanied by vomiting. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare skin blistering disorders. - Liver enzyme elevation: signs of hepatic stress detectable in blood tests. - Hypomagnesemia: low magnesium levels that may cause muscle cramps or cardiac arrhythmias. - Bone fracture risk: long‑term use may be associated with decreased bone density.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks. - Renal function assessment: adjust use in patients with severe renal impairment. - Hepatic impairment: use cautiously in moderate to severe liver disease. - Magnesium monitoring: prolonged therapy may require periodic serum magnesium checks. - Duration of therapy: limit long‑term use to approved indications to reduce fracture risk. - Drug‑interaction review: evaluate concomitant medications for possible interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Esomeprazole may alter the absorption or metabolism of several drugs; appropriate management is essential.

Major Interactions (Avoid): - Ketoconazole: reduced antifungal efficacy due to decreased gastric acidity. - Atazanavir: impaired antiretroviral absorption leading to subtherapeutic levels. - Nelfinavir: decreased protease inhibitor exposure. - Clopidogrel: reduced conversion to active metabolite, diminishing antiplatelet effect. - HIV protease inhibitors (e.g., ritonavir): altered plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect, requiring INR monitoring. - Digoxin: possible increase in serum levels. - Methotrexate: reduced clearance may raise toxicity risk. - Phenytoin: decreased antiepileptic levels. - Rifampin: may decrease esomeprazole exposure, affecting efficacy.